Dark Forest Capital Management’s Denali Therapeutics DNLI Stock Holding History

Dark Forest Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-28,433	Closed	-$398K	–	1233
2025 Q2	$398K	Sell	28,433 -52,387	-65%	-$737K	0.02%	973
2025 Q1	$1.1M	Buy	80,820 +67,932	+527%	+$1.3M	0.05%	648
2024 Q4	$263K	Buy	+12,888	New	+$330K	0.04%	715
2022 Q1	–	Sell	-529	Closed	-$24K	–	1385
2021 Q4	$24K	Sell	529 -66	-11%	-$3.13K	0.01%	624
2021 Q3	$30K	Buy	595 +592	+19,733%	+$33.4K	0.01%	705
2021 Q2	$0	Buy	+3	New	+$186	﹤0.01%	813

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dark Forest Capital Management's DNLI Position: Q3 2025 in Review

Dark Forest Capital Management sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 28,433 shares — an estimated $398K sold.

Dark Forest Capital Management first reported a position in DNLI in Q2 2021 and held it in 6 quarters. The position peaked at $1.1M in Q1 2025. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

Dark Forest Capital Management reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
Dark Forest Capital Management sold 28,433 Denali Therapeutics shares in Q3 2025, an estimated $398K.
Dark Forest Capital Management first reported a position in Denali Therapeutics in Q2 2021 and held it in 6 quarters.
Dark Forest Capital Management's Denali Therapeutics position peaked at $1.1M in Q1 2025.
240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Dark Forest Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.